Toggle navigation
Menu
Home
News
Local
National
World
Politics
Sports
Entertainment
Business
Health
News Tip Hotline
Weather
Bend
Traffic
Live Traffic Cams
Central Oregon
Mountain Passes
Road Reports
Trip Check
Gas Prices
Closures and Delays
Stations
KQAK-FM 105.7
The Peak 104.1
The Ranch 95.7 FM
KBNW-AM/FM
KRCO-AM
Events
Upcoming
Concerts
Submit An Event
Submit A PSA
Interviews
Inside Central Oregon
Central Oregon Spotlight
Water Wise Tips
HBG Interviews
Ray’s Random Questions
Just Used Cars as Heard on KQAK & The Ranch
About MCO
Contact/About Us
Advertise
Careers
Media Kit
Radio Stations
Contest Rules
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Industrial Estimate
Composite Estimate
500 Stocks Estimate
Gold
Crude Oil
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Articles published by Pharvaris N.V.
< Previous
1
2
3
Next >
Pharvaris Announces Clinical Trial Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at the 2025 US HAEA National Summit
June 27, 2025
From
Pharvaris N.V.
Via
GlobeNewswire
Tickers
PHVS
Pharvaris Presents Data Highlighting the Potential for Deucrictibant to Prevent and Treat Bradykinin-Mediated Angioedema Attacks at the EAACI Congress
June 16, 2025
From
Pharvaris N.V.
Via
GlobeNewswire
Tickers
PHVS
Pharvaris Announces Annual Meeting of Shareholders
June 10, 2025
From
Pharvaris N.V.
Via
GlobeNewswire
Tickers
PHVS
Pharvaris Presents Data Supporting Ongoing Clinical Development of Deucrictibant in Bradykinin-Mediated Angioedema
June 02, 2025
From
Pharvaris N.V.
Via
GlobeNewswire
Tickers
PHVS
Pharvaris to Present Deucrictibant Clinical Data and Exploratory Biomarker Data at Upcoming Congresses
May 19, 2025
From
Pharvaris N.V.
Via
GlobeNewswire
Tickers
PHVS
Pharvaris Reports First Quarter 2025 Financial Results and Provides Business Update
May 13, 2025
From
Pharvaris N.V.
Via
GlobeNewswire
Tickers
PHVS
Pharvaris to Host a Virtual R&D Call “Deucrictibant: Beyond HAE Type 1/2” on June 4
May 12, 2025
From
Pharvaris N.V.
Via
GlobeNewswire
Tickers
PHVS
Pharvaris Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
April 07, 2025
From
Pharvaris N.V.
Via
GlobeNewswire
Tickers
PHVS
Pharvaris Announces Orphan Designation Granted to Deucrictibant by the European Commission
April 01, 2025
From
Pharvaris N.V.
Via
GlobeNewswire
Tickers
PHVS
Pharvaris Presents Long-Term Clinical Data of Deucrictibant for the Prevention and Treatment of HAE Attacks at the 2025 AAAAI/WAO Joint Congress
March 03, 2025
From
Pharvaris N.V.
Via
GlobeNewswire
Tickers
PHVS
Pharvaris to Participate in the Leerink Partners Global Healthcare Conference 2025
March 03, 2025
From
Pharvaris N.V.
Via
GlobeNewswire
Tickers
PHVS
Pharvaris Outlines 2025 Strategic Priorities
January 13, 2025
From
Pharvaris N.V.
Via
GlobeNewswire
Tickers
PHVS
Pharvaris Reports Third Quarter 2024 Financial Results and Highlights Recent Business Updates
November 13, 2024
From
Pharvaris N.V.
Via
GlobeNewswire
Tickers
PHVS
Pharvaris to Participate in the Guggenheim Healthcare Innovation Conference
November 12, 2024
From
Pharvaris N.V.
Via
GlobeNewswire
Tickers
PHVS
Pharvaris Presents Clinical and Non-Clinical Data Supporting HAE Development Program at the 2024 ACAAI Annual Scientific Meeting
October 24, 2024
From
Pharvaris N.V.
Via
GlobeNewswire
Tickers
PHVS
Pharvaris Announces Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at Upcoming Scientific Meetings
October 16, 2024
From
Pharvaris N.V.
Via
GlobeNewswire
Tickers
PHVS
Pharvaris to Host Virtual Investor Event on October 23, 2024
October 15, 2024
From
Pharvaris N.V.
Via
GlobeNewswire
Tickers
PHVS
Pharvaris Announces Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at the 2024 HAEi Global Leadership Workshop
October 03, 2024
From
Pharvaris N.V.
Via
GlobeNewswire
Tickers
PHVS
Pharvaris Provides Business Update and Expands Development Program for Deucrictibant
September 05, 2024
From
Pharvaris N.V.
Via
GlobeNewswire
Tickers
PHVS
Pharvaris Presents Deucrictibant Long-Term Extension Data for Both the Prophylactic and On-Demand Treatment of HAE at the Bradykinin Symposium 2024
September 05, 2024
From
Pharvaris N.V.
Via
GlobeNewswire
Tickers
PHVS
Pharvaris Presents Data at the Bradykinin Symposium 2024
September 05, 2024
From
Pharvaris N.V.
Via
GlobeNewswire
Tickers
PHVS
Deucrictibant Clinical, Real-World, Nonclinical, and Discovery Data to be Presented at the Bradykinin Symposium
August 28, 2024
From
Pharvaris N.V.
Via
GlobeNewswire
Tickers
PHVS
Pharvaris Reports Second Quarter 2024 Financial Results and Provides Business Update
August 14, 2024
From
Pharvaris N.V.
Via
GlobeNewswire
Tickers
PHVS
Pharvaris Announces Annual Meeting of Shareholders
June 11, 2024
From
Pharvaris N.V.
Via
GlobeNewswire
Tickers
PHVS
Pharvaris Highlights Properties of Deucrictibant in Data Presentations at Recent Congresses
June 04, 2024
From
Pharvaris N.V.
Via
GlobeNewswire
Tickers
PHVS
Pharvaris to Present Clinical and Nonclinical Data at Upcoming Congresses
May 13, 2024
From
Pharvaris N.V.
Via
GlobeNewswire
Tickers
PHVS
Pharvaris Reports First Quarter 2024 Financial Results and Provides Business Update
May 08, 2024
From
Pharvaris N.V.
Via
GlobeNewswire
Tickers
PHVS
Pharvaris Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
April 10, 2024
From
Pharvaris N.V.
Via
GlobeNewswire
Tickers
PHVS
Pharvaris Appoints David Nassif, J.D., as Chief Financial Officer
April 10, 2024
From
Pharvaris N.V.
Via
GlobeNewswire
Tickers
PHVS
Pharvaris to Present Deucrictibant Clinical Data at the CIIC Spring 2024 Conference
April 04, 2024
From
Pharvaris N.V.
Via
GlobeNewswire
Tickers
PHVS
< Previous
1
2
3
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
581446795
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/60.0.3112.113 Safari/537.36
00fbf3724072e3a4c643b60a8db5a8756c4f8c05
1
